Table 6.
Meningococcal sequelae. Costs (no discount rate) were measured in € at January 2013 values.
| Parameters |
Base Case |
Distribution |
|---|---|---|
| Annual direct costs (1 case) | ||
| Amputation with substantial disabilitya | 7,339 | Gamma (25; 293.6) |
| Anxietyb | 1,146 | Gamma (25; 45.8) |
| Arthritis(1-y cost)c | 1,184 | Gamma (25; 47.4) |
| Depressiond | 3,192 | Gamma (25; 127.7) |
| Motor deficitse | 7,682 | Gamma (25; 307.3) |
| Blindnessf | 4,076 | Gamma (25; 163.0) |
| Epilepsy or seizureg | 2,272 | Gamma (25; 90.9) |
| Severe neurological disabilityh | 94,880 | Gamma (25; 3795.0) |
| Mental retardation (cognitive problems)e | 7,507 | Gamma (25; 300.3) |
| Hearing loss requiring cochlear implantationa | 6,327 | Gamma (25; 253.1) |
| Moderate/severe bilateral/unilateral hearing lossa | 3,163 | Gamma (25; 126.5) |
| Skin necrosisa | 1,066 | Gamma (25; 42.6) |
| Scarsh | 533 | Gamma (25; 21.3) |
| Severe speech or communication problemsi | 9,796 | Gamma (25; 391.8) |
| Renal failurel | 56,126 | Gamma (25; 2245.0) |
| Chronic migrainem |
892 |
Gamma (25; 35.7) |
| |
Annual indirect costs (1 case) |
|
| Special case education*h | 14,566 | Gamma (25; 582.2) |
| Lost productivity of parent^n | 24,500 | Gamma (25; 980.0) |
| Lost productivity of patient°o | 24,500 | Gamma (25; 980.0) |
According to [53];
According to [80];
According to [81];
According to [82];
According to [83];
According to [84];
According to [85,86];
According to [87];
According to [30];
According to [88];
According to [89];
According to [90,91,92];
According to [90,92,93].
Applied to: motor deficits, blindness, epilepsy or seizure, mental retardation (cognitive problems), hearing loss and severe speech or communication problems.
Applied to: mental retardation (cognitive problems), severe neurological disability, severe speech or communication problems, epilepsy, blindness, motor deficit, severe amputations and hearing loss.
Applied to: severe amputations, anxiety, depression, motor deficit, blindness, epilepsy or seizure, severe neurological disability, mental retardation (cognitive problems), Hearing loss requiring cochlear implantation, Moderate/severe bilateral/unilateral hearing loss, renal failure, severe speech or communication problems.